{Reference Type}: Journal Article
{Title}: NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.
{Author}: von Mehren M;Kane JM;Riedel RF;Sicklick JK;Pollack SM;Agulnik M;Bui MM;Carr-Ascher J;Choy E;Connelly M;Dry S;Ganjoo KN;Gonzalez RJ;Holder A;Homsi J;Keedy V;Kelly CM;Kim E;Liebner D;McCarter M;McGarry SV;Mesko NW;Meyer C;Pappo AS;Parkes AM;Petersen IA;Poppe M;Schuetze S;Shabason J;Spraker MB;Zimel M;Bergman MA;Sundar H;Hang LE;
{Journal}: J Natl Compr Canc Netw
{Volume}: 20
{Issue}: 11
{Year}: 11 2022
{Factor}: 12.693
{DOI}: 10.6004/jnccn.2022.0058
{Abstract}: Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.